Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The EMPA-REG, CANVAS, and DECLARE-TIMI 58 studies revealed that SGLT2 inhibitors reduce the risk of cardiovascular events and concomitantly suggested that these drugs slow the progression of kidney disease in type 2 diabetes.
|
31725011 |
2020 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The renoprotective action of SGLT-2 inhibitors is strongly supported by human studies showing that these agents prevent the progression of albuminuria and retard nephropathy progression to ESRD.
|
29792136 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
SGLT2 inhibitors reduced the risk of dialysis, transplantation, or death due to kidney disease in individuals with type 2 diabetes and provided protection against acute kidney injury.
|
31495651 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Subgroup analysis from these major trials indicated a reduction in progression of nephropathy and HF readmission with SGLT2 inhibitors.
|
31627834 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of sodium-glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis-related kidney disease.
|
31561285 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Compared with controls, SGLT2 inhibitors significantly reduced the risk of microalbuminuria (RR, 0.69; 95% CI, 0.49 to 0.97; P = 0.032), macroalbuminuria (RR, 0.49; 95% CI, 0.33 to 0.73; P < 0.001), and worsening nephropathy (RR, 0.73; 95% CI, 0.58 to 0.93; P = 0.012).
|
31506585 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This review considers anew the etiology of the cardio-renal protective effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors by extending the discussion to renal congestion, inherent in diabetic kidney disease (DKD) even at an early stage of nephropathy in which heart failure (HF) or salt and water accumulation is asymptomatic.
|
31291624 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
|
31310751 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Although sodium-glucose cotransporter-2 (SGLT2) inhibitors were reported to lower blood pressure (BP) in type 2 diabetes mellitus, whether they have a role in nondiabetic hypertensive kidney diseases is unclear.
|
31537914 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, there is growing evidence to illustrate the overall safety profile of this class of agents and support the benefit-risk profile of SGLT2 inhibitors as a preferred option following metformin monotherapy failure, with respect to both kidney disease progression and heart failure outcomes.
|
31410711 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have important cardiovascular and renal benefits in adults with type 2 diabetes who have or are at high risk of cardiovascular and renal disease.
|
31377891 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.
|
30929540 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Even with recent studies employing SGLT2 inhibitors demonstrating protection against cardiovascular and kidney diseases, kidney function continues to decline in people with established diabetic kidney disease (DKD).
|
31693730 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review we have discussed the potential synergistic and/or additive effects of GLP 1 RA and SGLT2 inhibitors on the primary onset and progression of kidney disease, and the potential implications on current guidelines of diabetes type 2 management.
|
31757028 |
2019 |
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We quantified renal SGLT mRNA expression in healthy controls (HC), glomerulonephritis (GN), and diabetic kidney disease (DKD) to identify differences in expression across a spectrum of renal diseases. mRNA expression of SGLT1 and SGLT2 in renal tubules and glomeruli, obtained using microdissection and microarray techniques, was evaluated in two large cohorts.
|
31545924 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular safety, have revealed that these medications have a preventative advantage on adverse cardiovascular outcomes, including worsening of heart failure and deterioration of nephropathy, in patients with type 2 diabetes (T2D).
|
31440988 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Our aim is to review the rationale for renal protection with SGLT2 inhibitors, and their current place in the clinical management of patients with kidney disease.
|
29735306 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, SGLT2 inhibitors could constitute a novel therapeutic target for the treatment of type 2 diabetes with overt nephropathy.
|
29374293 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent randomized clinical trials in high cardiovascular risk patients with type 2 diabetes suggest that the unique effects of SGLT2 inhibitors on blood pressure and body weight may translate into reduced cardiovascular events and slowed kidney disease progression.
|
29349558 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Sodium glucose co-transporter 2 (SGLT2) inhibitors appear to protect against increased risks of cardiovascular and kidney disease in patients with type 2 diabetes but also cause some harms.
|
29604389 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, SGLT2 inhibition prevents further renal function deterioration and death from kidney disease in these patients.
|
29482993 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Available English-language data from reviews, abstracts, presentations, and clinical trials of use of SGLT2 therapy specifically detailing outcomes on CV and renal disease in humans were reviewed.
|
29911393 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Since hyperglycemia contributes to arterial stiffness, we hypothesized that the SGLT2 inhibitor empagliflozin (EMPA) would improve endothelial function, reduce aortic stiffness, and attenuate kidney disease by lowering hyperglycemia in type 2 diabetic female mice (db/db).
|
30060748 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.
|
30089717 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that the SGLT2 inhibitor ipragliflozin prevents progression to diabetic overt nephropathy in uninephrectomized type 2 diabetic mice.
|
29702076 |
2018 |